Cancer discovery
-
The Food and Drug Administration Amendments Act requires researchers to submit clinical trial results to ClinicalTrials.gov within a year of completion. However, a new study indicates that only 13.4% of trials comply.
-
Data from the phase II TOPARP-A clinical trial indicate that men with metastatic castration-resistant prostate cancer are more likely to respond to the PARP inhibitor olaparib if they have mutations in DNA damage repair genes. The study provides the first data supporting molecular stratification for patients with this disease.